Source: NICE
Area: News
NICE has published a costing statement to accompany its guidance on the use of ranibizumab for treating visual impairment due to diabetic macular oedema (TA 274).
The costing report calculates that: “the annual cost associated with implementing this recommendation is estimated as £41,000 for a population of 100,000 based on the standard assumptions in the model once a steady state is reached. There are also anticipated to be non-recurrent costs from treating the prevalent population on implementation of the guideline of around £341,000. It is (Read more...)
Month: February 2013
Excercise After PVD is Safe
I believe exercise after sustaining a posterior vitreous detachment (PVD) to be safe. Many doctors recommend a “no exercise” period after a PVD to decrease the risk of retinal tear and retinal detachment. This does not make sense to me. PVD Causes Retinal Tear A retinal tear may occur after a posterior vitreous detachment, but […]
Global eye health company, Bausch + Lomb, names Robert Bertolini as president and chief financial officer
Bausch + Lomb, the global eye health company, has named Robert Bertolini as president and chief financial officer effective immediately. In this capacity, he will oversee the company’s Finance, Information Technology and Global Quality and Operations (…
Ampio Pharmaceuticals starts Optina clinical trial
Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.
RNFL changes portend glaucomatous visual field progression
Structural morphology correlated significantly with functional loss in patients with glaucoma and suspected glaucoma, according to a study.The prospective clinical trial included 310 glaucoma suspect and preperimetric eyes and 177 perimetric eyes that …
‘Heads-up’ 3-D cataract surgery performed in Asia
High-definition 3-D “heads-up” cataract surgery is now being performed in Asia, according to a news release from TrueVision.Clement C.Y. Tham, MD, an OSN APAO Edition Board Member and the first surgeon to perform the procedure in Asia, completed eight …
Carl Zeiss Meditec introduces data management options for Forum system
Carl Zeiss Meditec has announced the release of new management software and a glaucoma management application to expand the offerings of its Forum eye care data management system.The Forum Glaucoma Workplace will allow physicians to combine Cirrus optical coherence tomography and Humphrey Field Analyzer perimetry information and interactively review patients’ visual field data, according to a news release.
Additional glaucoma videos: Individualized surgery, additional Q&A and more
Click to view four recently posted glaucoma videos from Hawaiian Eye 2013.
Vision CRC develops retinal camera for detection of blinding eye disease and general health disorders
The most advanced technology for use in real-time detection and assessment of common blinding eye disease and general health disorders will soon be available to the world with stimulus funding provided for development by the Australian Government’s CRC…
Potential Diagnostic Test For River Blindness Infection
Scientists at The Scripps Research Institute (TSRI) have found a telltale molecular marker for Onchocerciasis or “river blindness,” a parasitic infection that affects tens of millions of people in Africa, Latin America and other tropical regions. The …
Visual Outcomes in Children With Neurofibromatosis Type 1 and Orbitotemporal Plexiform Neurofibromas – Corrected Proof
Purpose: To describe the visual outcomes and volumetric magnetic resonance imaging (3D MRI) in children with neurofibromatosis type 1 (NF1) and orbitotemporal plexiform neurofibromas.Design: Multicenter retrospective case series.Methods: Two institutio…
Topical Linezolid 0.2% for the Treatment of Vancomycin-Resistant or Vancomycin-Intolerant Gram-Positive Bacterial Keratitis – Corrected Proof
Purpose: To report the successful use of topical linezolid 0.2% in the treatment of gram-positive bacterial keratitis.Study Design: Retrospective, interventional case series.Methods: All cases of bacterial keratitis treated at the University of Illinoi…
Holography Stimulates Optogenetically Photosensitized Retinal Nerve Cells to Restore Vision
Newly developed light sensitive proteins, genetically introduced into retinal nerve cells, may lead to the ability to restore vision in the blind. One challenge in developing a real-world system is that these protein activated neurons require a high energy light source for them to send electrical signals to the brain. Moreover, this light source n (Read more...)
OptiMedica gains patent for laser cataract surgery technology
The U.S. Patent and Trademark Office will issue a fundamental patent to OptiMedica related to laser cataract surgery technology, according to a company news release.Patent No. 8394084, to be issued March 12, will cover a three-dimensional femtosecond l…
Joseph Colin, MD, dies of cancer
Joseph Colin, MD, an OSN Europe Edition Board Member, ophthalmic surgeon and educator, died Feb. 24 of metastatic renal cancer. At the time of his death, Colin was the chairman of the Department of Ophthalmology at Bordeaux University Medical School an…
Eylea drives increase in net income for Regeneron
Regeneron Pharmaceuticals reported a net income of $750.3 million in 2012, compared with a net loss of $221.8 million in 2011, according to a company press release.Revenues increased from $445.8 million in 2011 to $1.4 billion in 2012. Eylea (aflibercept) accounted for $838 million in U.S. net sales in 2012, leading to Regeneron’s first full year of profitability, according to the release.
More new glaucoma videos: Advances in imaging, combined cataract and glaucoma, IOP at home and more
Click to view four recently posted glaucoma videos from Hawaiian Eye 2013.
In Mice With Myotonic Dystrophy, Drug Delivery Strategy Eliminates Myotonia Symptoms
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. New classes of drugs cal…
Comparison of Cone Pathologic Changes in Idiopathic Macular Telangiectasia Types 1 and 2 Using Adaptive Optics Scanning Laser Ophthalmoscopy – Corrected Proof
Purpose: To compare pathologic changes in the photoreceptors of eyes with idiopathic macular telangiectasia types 1 and 2 using adaptive optics scanning laser ophthalmoscopy (AO-SLO).Design: Prospective cross-sectional study.Methods: Eleven eyes with idiopathic macular telangiectasia type 1, 14 eyes with type 2, and 10 normal eyes underwent a full ophthalmologic examination, spectral-domain optical coherence tomography (SD-OCT), and imaging with an original prototype AO-SLO system. All eyes with idiopathic macular telangiectasia were examined with fluorescein angiography (FA), confocal blue reflectance, and microperimetry.Results: Compared with normal eyes (29 017 ± 5507 cones/mm2), those with idiopathic macular telangiectasia type 1 had significantly lower cone density (Read more...)
Correlation Between Quantitative Measurements of Tear Film Lipid Layer Thickness and Meibomian Gland Loss in Patients With Obstructive Meibomian Gland Dysfunction and Normal Controls – Corrected Proof
Purpose: To evaluate the correlation between tear film lipid layer thickness and other objective measurements such as tear film break-up time (TBUT), upper and lower meibomian gland losses, and Schirmer 1 test in patients with obstructive meibomian gland dysfunction (MGD) and normal controls.Design: Cross-sectional study.Methods: Thirty eyes of 30 patients with obstructive MGD and 25 eyes of 25 normal controls were enrolled. Lipid layer thickness was measured using an interferometer. Tear film stability and tear production were evaluated by TBUT and Schirmer 1 test. Upper and lower meibomian gland losses were evaluated using noncontact meibography. The correlations among variables were (Read more...)